Introduction: Frey's Syndrome is defined by facial hyperhidrosis in the preauricular region unleashed by gustatory stimulus and caused mainly by parotidectomy. Several treatment and prevention measures have been proposed, with no conclusive results. Recently, injections of Botulinum Toxin have been suggested, obtaining encouraging results. The objective is to describe our experience in treating Frey's Syndrome with this drug.
Materials And Method: Between 2004 and 2007, our team treated 10 patients suffering from Frey's Syndrome. All cases were caused by parotid resection. In 60%of cases a complete elevation of the SMAS (superficial musculoaponeurotic system) was carried out. In the remaining cases, such elevation was either not made or the SMAS was severely damaged. All patients were treated with intradermic injections of Botulinum Toxin. Recorded data were: units administered, affected area, time lapse until improvement in the symptoms, and the evolution after one, six and twelve months after the injection. Possible side effects were also recorded.
Results: The average treated area per patient was 26 cm2. An average of 38 units of Botulinum Toxin per patient was injected. Average time lapse until improvement was 5.5 days. Five patients were injected with a second dose after an average of 18 months from the first injection. On this occasion, the area affected was considerably smaller than that presented before the first injection. The most frequently reported side effect was dry mouth.
Conclusion: Our team considers that treating Frey's Syndrome with Botulinum Toxin is effective. The effects of the treatment are long-lasting and side effects are minimal and temporary. A second injection is needed after 15 to 18 months of the first, although the affected area is usually smaller.
Download full-text PDF |
Source |
---|
Niger J Clin Pract
November 2024
Department of Pathology, Kayseri City Training and Research Hospital, Kayseri, Turkey.
Background: Deep-lobe tumors have been shown to possess a significantly thicker capsule with less tumor penetration compared to superficial tumors. Thus, more conservative surgical approaches, rather than aggressive methods, have been proposed for treating benign deep-lobe tumors of the parotid gland.
Aim: To evaluate the surgical outcomes and oncological safety of selective deep-lobe parotidectomy (SDLP) in patients with benign lesions located in the deep lobe of the parotid gland.
J Maxillofac Oral Surg
December 2024
Maxillofacial Surgery UnitDepartmentof Medicine and SurgeryDepartment of Neurosciences, Reproductive and Odontostomatological Sciences, University Federico II, Via Sergio Pansini 5, 80131 Naples, Italy.
Background: This is an observational cohort study on patients affected by malignant parotid tumors treated with total parotidectomy. The aim of our work is to analyze and compare the effects and complications after parotidectomy, using or not SurgiMend ®.
Methods: 40 patients were retrospectively enrolled between September 2014 and June 2020.
J Stomatol Oral Maxillofac Surg
November 2024
Department of Oral and Maxillofacial Surgery, Klinikum Dortmund and Witten/Herdecke University, Dortmund/ Witten, Germany.
BMC Surg
November 2024
General Practice, People's Hospital of Anshun City, Guizhou, 561000, China.
Background: This study aimed to analyze the effects of anterior descending mandible (ADM) and free superior mesenteric artery (SMAS) folding flaps on post-parotidectomy facial depression.
Methods: This retrospective study examined the effects of sex, age, surgical sample size, method, duration, and blood loss on postoperative complications in 65 patients.
Results: No significant differences involving sex, age, or sample size for surgical resection were observed between the two groups.
N Engl J Med
September 2024
Tri-Service General Hospital, Taipei, Taiwan
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!